CA3149112A1 - Novel therapeutic use - Google Patents
Novel therapeutic use Download PDFInfo
- Publication number
- CA3149112A1 CA3149112A1 CA3149112A CA3149112A CA3149112A1 CA 3149112 A1 CA3149112 A1 CA 3149112A1 CA 3149112 A CA3149112 A CA 3149112A CA 3149112 A CA3149112 A CA 3149112A CA 3149112 A1 CA3149112 A1 CA 3149112A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- pole
- inhibitor
- compound
- deficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2019/052243 WO2021028644A1 (en) | 2019-08-09 | 2019-08-09 | Novel therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3149112A1 true CA3149112A1 (en) | 2021-02-18 |
Family
ID=74570294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3149112A Pending CA3149112A1 (en) | 2019-08-09 | 2019-08-09 | Novel therapeutic use |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220387544A1 (https=) |
| EP (1) | EP4010002A1 (https=) |
| JP (2) | JP2023501038A (https=) |
| CN (1) | CN114728036A (https=) |
| CA (1) | CA3149112A1 (https=) |
| WO (1) | WO2021028644A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12358886B2 (en) * | 2019-08-09 | 2025-07-15 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
| EP4455129A4 (en) * | 2021-12-30 | 2025-05-07 | Shanghai Apeiron Therapeutics Company Limited | Dna polymerase theta inhibitor and use thereof |
| TW202332442A (zh) | 2022-01-31 | 2023-08-16 | 瑞士商瑞森製藥公司 | ＰＯＬθ抑制劑 |
| WO2024197653A1 (en) * | 2023-03-29 | 2024-10-03 | Suzhou Eoc Medical Research Co., Ltd. | Heterocyclic compounds and uses thereof |
| WO2025011603A1 (zh) * | 2023-07-12 | 2025-01-16 | 南京再明医药有限公司 | 一种化合物用于预防或治疗53BP1/Shieldin复合物缺陷的癌症的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013133876A1 (en) * | 2011-12-07 | 2013-09-12 | The Regents Of The University Of California | Biomarkers for prediction of response to parp inhibition in breast cancer |
| WO2017070198A1 (en) * | 2015-10-19 | 2017-04-27 | Dana-Farber Cancer Institute, Inc. | Polymerase q as a target in hr-deficient cancers |
| US12358886B2 (en) * | 2019-08-09 | 2025-07-15 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
-
2019
- 2019-08-09 CA CA3149112A patent/CA3149112A1/en active Pending
- 2019-08-09 JP JP2022507857A patent/JP2023501038A/ja not_active Ceased
- 2019-08-09 CN CN201980101223.8A patent/CN114728036A/zh active Pending
- 2019-08-09 WO PCT/GB2019/052243 patent/WO2021028644A1/en not_active Ceased
- 2019-08-09 US US17/597,940 patent/US20220387544A1/en not_active Abandoned
- 2019-08-09 EP EP19755666.5A patent/EP4010002A1/en not_active Withdrawn
-
2024
- 2024-01-31 JP JP2024012755A patent/JP2024059632A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023501038A (ja) | 2023-01-18 |
| WO2021028644A1 (en) | 2021-02-18 |
| US20220387544A1 (en) | 2022-12-08 |
| CN114728036A (zh) | 2022-07-08 |
| EP4010002A1 (en) | 2022-06-15 |
| JP2024059632A (ja) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4010329B9 (en) | Deuterated compounds for use in the treatment of cancer | |
| US20220387544A1 (en) | Novel therapeutic use | |
| AU2024205010A1 (en) | CSF1R inhibitors for use in treating cancer | |
| US20240166623A1 (en) | Novel process | |
| ES2986019T3 (es) | Tratamientos contra el cáncer que usan combinaciones de inhibidores de ERK y MEK de tipo 2 | |
| TW201642859A (zh) | Ｍｄｍ２抑制劑及ｂｔｋ抑制劑之倂用治療法 | |
| EP4419526B1 (en) | Heterocyclic compounds for use in the treatment of cancer | |
| TW202320792A (zh) | 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法 | |
| WO2015095833A1 (en) | Treatment of hematologic cancers | |
| HK40076656A (en) | Deuterated compounds for use in the treatment of cancer | |
| HK40076656B (en) | Deuterated compounds for use in the treatment of cancer | |
| WO2024218499A1 (en) | Heterocyclic inhibitors of dna polymerase theta for the treatment of cancer | |
| HK40112378B (en) | Heterocyclic compounds for use in the treatment of cancer | |
| HK40112378A (en) | Heterocyclic compounds for use in the treatment of cancer | |
| CN118632696A (zh) | 包含fgfr抑制剂和kras抑制剂的组合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240806 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240806 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241113 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250411 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |